If you had polled a group of thousands of Mets fans before the 2023 season, asking them whether they wanted the team to sign Shohei Ohtani or Yoshinobu Yamamoto this offseason, some of them would've asked who Yamamoto was.
Many others would've of course known that Yamamoto was the best pitcher in Japan -- a young ace who was a season away from being posted for MLB teams.
Still, that group would've likely laughed a bit before choosing Ohtani as the player they wanted the Mets to sign. And that would've made all the sense in the world.
Now?
Ohtani's future -- at least as it pertains to him continuing to be the unicorn that made him the best player in baseball history -- is up in the air.
And it isn't just that Ohtani underwent elbow surgery that will prevent him from pitching in 2024 -- it's that this is his second Tommy John-like procedure.
Could Ohtani be back on the mound for the start of the 2025 season -- his age-30 campaign -- resembling the pitcher he was over the last few seasons? Sure. But he could also return in seriously diminished fashion, like Mike Clevinger or Noah Syndergaard.
There are success stories for pitchers who had TJS twice, such as Nathan Eovaldi. But with Ohtani possibly receiving a salary that will pay him $45 million or $50 million annually for 10 seasons or more, it's an incredibly risky proposition -- especially since he'll be attempting to rehab his elbow in 2024 while focusing his attention on hitting.
Would it be amazing for the Mets to land Ohtani, who was an MVP candidate this season just based on his hitting alone? Absolutely.
But when you factor in the money Ohtani will command, the length of the contract he could get, the uncertainty surrounding his future on the mound, and the fact that he's strictly a DH when he's not on the mound, it's not hard to think the prudent decision is to take a pass.